LivaNova stock came into earnings with a modest 3 month gain, then dropped about 8% to roughly US$78 after the Q2 release. That is a sharp reaction for a medical device company that just posted record quarterly revenue near US$391m and a jump in basic earnings per share to about US$1.97.

The expectation gap is clear. Investors had been treating LivaNova as a cleaner profitability story. However, the headline this quarter is about a powerful earnings swing and raised guidance sitting alongside lower free cash flow and higher capital spending. The rest of this report unpacks that mix.

Love the strong earnings swing at LivaNova but concerned about the weaker free cash flow and higher capital spending? Check out list of solid balance sheet and fundamentals stocks (50 results) for stocks that combine profitability with sturdier cash generation and balance sheets.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$390.6m vs. US$352.5m (up about 10.8%)
• Net Income, Q2 2026 vs. Q2 2025: US$108.6m vs. US$27.2m (very large increase, about 4x)
• Basic EPS, Q2 2026 vs. Q2 2025: US$1.97 vs. US$0.50 (very large increase, about 4x)
• Trailing 12 Month Revenue, Q2 2026 vs. Q2 2025: US$1.47b vs. US$1.31b (up about 12.4%)

Tired of scrolling through dense tables and raw figures to understand LivaNova? See the full visual breakdown of LivaNova's valuation story in an easy dashboard format with the company report for LivaNova.

LivaNova bull case leans on execution and guidance

Bulls argue that LivaNova is turning its cardiopulmonary and neuromodulation portfolio into a higher quality, recurring revenue engine with improving margins and cash generation. Q2 offers real progress on the operating side. Cardiopulmonary revenue of US$222m with Essenz heart lung machine placements rising toward management’s 80% of placements target for 2026 supports the upgrade cycle story. Epilepsy revenue grew around 10% with help from better realized pricing, improved Medicare reimbursement and CORE data, which fits the thesis of data driven adoption and pricing power. Adjusted gross margin reached 71% and adjusted operating margin about 23%, and full year revenue and EPS guidance both moved higher. However, adjusted free cash flow slipped slightly to US$46m and full year free cash flow guidance went lower while capex guidance rose to US$135m. That means the profitability story is progressing but not yet converting cleanly into cash.

LivaNova bear case focuses on cash and expectations reset

The bear narrative centers on rich expectations around LivaNova, execution risk in OSA and neuromodulation, and pressure on cash generation. The 8.4% share price drop after earnings suggests a reset in those expectations despite record revenue and higher EPS guidance. Bears worried that heavy spending would weigh on free cash flow have some support. Adjusted free cash flow declined slightly year on year, and management cut full year free cash flow guidance while lifting capex from US$120m to US$135m. Concerns about regulatory and timing risk in OSA are also visible. The PMA supplement for PolySync in obstructive sleep apnea has slipped into a wider H2 2026 to H1 2027 window. Earlier news of modest insider selling and prior flags around the stock trading above intrinsic value estimates now sit beside a weaker recent share price trend.

After lower free cash flow guidance, rising capex and timing risk around LivaNova’s OSA path, review whether these are early signs of deeper structural issues by reading our risk analysis for LivaNova which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If the mix of stronger earnings and softer free cash flow at LivaNova has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how guidance and cash metrics evolve. After you decide to take a position, keep your focus on what matters most by using the Portfolio Command Center to surface only the key developments across your holdings. For longer term planning, tap into the crowd insights and debate inside the Community to see how other investors are thinking about the same risks and opportunities. By spotting hidden catalysts and potential red flags early, you give yourself a better chance of staying ahead of the market over time.

Seeking Alternatives Beyond LivaNova Today

Fresh stock ideas do not stay quiet for long. Breakout moves, fading weakness and under the radar stories get caught quickly. Scan these themed lists before the crowd and act now.

• Spot early momentum in smaller AI players by reviewing the curated group of 30 AI small caps while they are still under most investors’ radar.
• Hunt for resilient balance sheet strength with the hand picked list of solid balance sheet and fundamentals stocks (50 results) before market momentum turns these quiet compounders into fast moving stocks.
• Target powerful income potential in today’s market by zeroing in on the carefully filtered 8 dividend fortresses while yields and prices still look appealing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.